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Neurodegenerative diseases are characterized by the aggrega-
tion ofmisfolded proteins in the brain. Among these disorders are
the prion diseases, which are transmissible, and in which the mis-
folded proteins (“prions”) are also the infectious agent. Increas-
ingly, it appears that misfolded proteins in Alzheimer and Parkin-
son diseases and the tauopathies also propagate in a “prion-like”
manner. However, the association between prion formation,
spread, and neurotoxicity is not clear. Recently, we showed that in
prion disease, protein misfolding leads to neurodegeneration
through dysregulation of generic proteostaticmechanisms, specif-
ically, theunfoldedproteinresponse.Geneticandpharmacological
manipulation of the unfolded protein response was neuroprotec-
tive despite continuing prion replication, hence dissociating this
fromneurotoxicity. Thedata have clear implications for treatment
across the spectrum of these disorders, targeting pathogenic pro-
cesses downstream of proteinmisfolding.
The “prion-like” nature of several neurodegenerative dis-
eases has been proposed for a number of years. The central
concept is the spread of self-propagating misfolded proteins
from neuron to neuron throughout the brain, associated with
more or less stereotypical patterns of neurodegeneration for
specific diseases. Apart from prion protein (PrP)2 in the arche-
typal prion diseases (typified by Creutzfeldt-Jakob disease
(CJD)), the evidence that amyloid-1–42 (A), Tau, and -sy-
nuclein all propagate through the brain is compelling, with
clear implications for the pathogenesis of Alzheimer disease,
frontotemporal dementias and other tauopathies, and Parkin-
son disease. The spread (within the brain, at least) of neurode-
generative diseases through protein misfolding appears to be a
truly generic phenomenon. However, the spread of misfolded
protein is not evidence of neurodegeneration, and this raises
critical questions about the link, or lack of it, between transmis-
sion of pathological proteins and their neurotoxic effects.What
is the relationship between toxicity and “infectivity” in classic
prion disease and other protein misfolding disorders? This
review will consider this relationship, and discusses the advan-
tages of focusing on neurotoxic pathways, downstream of the
prion replication process, for treatment of this group of
disorders.
Prion Formation in Prion Disease
Prion diseases are fatal transmissible neurodegenerative dis-
orders of humans and other mammals (seeWatts and Prusiner
(53) in this series). The classic veterinary disorder is scrapie in
sheep; the most common human disease is CJD. The infectious
agent is nowwidely accepted to be a protein that self-replicates,
without the need for nucleic acids (1), confirming the “protein-
only hypothesis” of transmission of these disorders first postu-
lated by Griffith (2). The scrapie agent is a protein, present in
aggregated form, highly insoluble in non-ionic detergents and
partially protease-resistant, with a relative molecular mass of
27–30 kDa (3). Known as prion protein, PrP, it was found to be
encoded by an endogenous gene, PRNP (4), which, intriguingly,
was equally expressed in both infected and uninfected animals
(4, 5). The normal product of thePRNP gene is PrPC, for cellular
prion protein, a protease-sensitive protein of 33–35 kDa,
whereas the previously isolated disease-specific protein was
called PrPSc, for scrapie-associated prion protein. These two
isoforms of PrP share identical primary structures but differ in
secondary and tertiary structure. The central mechanism of
infectivity involves a change in the normal cellular isoform,
PrPC, into PrPSc (6). This conversion is thought to be a post-
translational change in conformation, which initiates the auto-
catalytic conversion of PrPC into PrPSc, by interaction with
existing PrPSc molecules. As neurons are depleted of PrPC,
newly synthesized PrPC providesmore substrate for conversion
to PrPSc, which accumulates, converting more PrPC, and so on
(Fig. 1).
Prion-like Spread in Other Neurodegenerative Diseases
The findings that Tau, A, and -synuclein are all capable of
the type of templated conformational change that was first
described for classic scrapie prions and that these changes
could spread between cells were first established in cell models
(7–9). Like classic prions, these proteins also form distinct con-
formers in vivo, and a number of elegant experiments con-
firmed that A, mutant Tau, and mutant -synuclein cause
spread in regional pathology and disease progression in mouse
models (10–13). More recently, the propagation and misfold-
ing of wild type -synuclein, giving rise to “sporadic”-type phe-
notypes in mice (12, 14), have been reported. Spread between
animals has also been reported (see Holmes and Diamond (54)
in this series), but transmission through repeated passage, as
defines classic prion diseases, has not been seen.
Despite the universality of the prion-like spreading phenom-
enon, not all these models, including both classic CJD/scrapie
and other protein folding diseases, show associated neurode-
generation, however. This raises the important concept that
protein misfolding disorders have two aspects: first, within cell
(i.e. cell-autonomous) processes that cause cellular dysfunction
and ultimately neurodegeneration, and second, between cell
(i.e.non-cell-autonomous) processes, throughwhich pathology
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spreads. The link between the two is not clear, but it is impor-
tant both for understanding diseasemechanisms and for direct-
ing treatments.
Dissociation of Prion Replication and Neurotoxicity
In the classic prion diseases, prion replication involves the
conversion of native prion protein (PrPC) into the protease-
resistant, disease-associated isoform that co-purifies with
infectivity, PrPSc (see above). Given its accumulation in the
brain and its capacity to transmit these fatal neurodegenerative
conditions, PrPSc was generally assumed to be the neurotoxic
species. However, the dissociation of toxic species (what kills
neurons) and infectious agent (propagating prion protein) is
now well established (15–17). Evidence for this dissociation
appeared as early as 1993, with the landmark experiments of
first Büeler et al. (18) and thenManson et al. (19), who showed
that in the absence of PrPC, PrPSc was not toxic to brains of
inoculated PrP-knock-out mice. Similarly, only wild type tissue
expressing PrPC grafted into the brains of PrP-null mice
showed neurotoxic effects of prion infection (20). However, the
key evidence came from the discovery of subclinical states of
prion infection, characterized by experimental animals that
were asymptomatic carriers of infectivity, never developing
clinical disease throughout their lifespan (extensively reviewed
by Hill and Collinge (16)). Similar subclinical states were
observed by others (21–23), and the converse situation, neuro-
degeneration with minimal levels of PrPSc, which was seen in
certain inherited human prion diseases (24, 25) and in animal
models (26), also supported the dissociation. Interestingly,
switching off prion conversion in neurons during the course of
prion infection, but allowing it to continue in astrocytes, leads
to profound neuroprotection and rescue of neurons from prion
toxicity despite massive extraneuronal accumulation of PrPSc
(15, 27, 28). Removing the glycosylphosphatidylinositol anchor
fromPrP releases it from the neuronal cell surface and similarly
prevents neurotoxicity (29) despite extensive extraneuronal
PrPSc accumulation (this occurs over time despite low levels of
expression of anchorless PrP in this model). Again, the findings
discussed above support the idea that PrPSc itself is not directly
toxic to neurons, but rather indicate that it is the process of
prion conversion within them that leads to downstream (indi-
rect) toxic effects. This is a critical finding as it implies the
presence of generic, cellular pathways mediating toxicity in
classic prion, and likely, in other neurodegenerative diseases.
This dissociation between prion propagation and neurotoxic
effect is sometimes seen in the other neurodegenerative dis-
eases. The landmark study by Clavaguera et al. (10), describing
prion-like transmission of mutant human P301S Tau in mice,
similarly showed spread of pathology, without neurodegenera-
tion, as did the recent report of wild type -synuclein (14). This
is in contrast to the propagation and disease in other models
(12, 13, 30). So cell-autonomous and non-cell-autonomous
mechanisms co-exist, but they do not necessarily impinge
equally on neurotoxicity in all cases. Both, however, clearly
result from the same central phenomenon: the accumulation of
misfolded proteins.
Generic Mechanisms of Neurotoxicity
The prion-like neurodegenerative disorders, including the
classic prion diseases, but also Alzheimer and Parkinson dis-
eases and the tauopathies, as well as amyotrophic lateral scle-
rosis, all share the two key features: accumulation of misfolded
proteins (irrespective of spread) and neuronal loss. We have
used prion-infected mice to understand the link between pro-
tein misfolding and neurodegeneration. Prion-diseased mice
are unique among mouse models of neurodegeneration as they
truly recapitulate the human disorders and have extensive neu-
ronal loss in association with accumulation of misfolded
protein.
We studied tg37mice used in our previous studies (15, 27, 28,
31–33). These mice overexpress PrP at around 3-fold wild type
levels and succumb to Rocky Mountain Laboratory (RML)
prion infection in around 12 weeks (31). Our first key observa-
tion biochemically was the finding that, in the context of
increasing prion replication and rising levels of misfolded PrP,
there was a sudden, abrupt reduction in the number of synaptic
proteins at 9 weeks post infection (wpi). This correlated with
critical reduction in both synapse number and neurotransmis-
sion and with accompanying behavioral decline and loss of
object recognitionmemory. It was closely followed by neuronal
loss, at 10 wpi (33). The reduction in synaptic protein levels at 9
wpi was clearly a catastrophic event, occurring at a critical
moment during the disease process. We asked whether this
drop reflected increased degradation of proteins or decreased
synthesis. The ubiquitin proteasome pathway is known to be
inhibited in prion disease, causing a reduction, not an increase,
in protein degradation (34). We therefore asked whether pro-
tein synthesis was reduced through altered translational con-
trol mechanisms. Specifically, we examined the role of the
unfolded protein response (UPR).
The Unfolded Protein Response
The UPR is a protective cellular mechanism that is induced
during periods of cellular and endoplasmic reticulum (ER)
stress, which aims to maintain protein-folding homeostasis
FIGURE 1. Schematic of prion conversion. Native prion protein (PrPC;
blue circular shapes) is converted into PrPSc (black hexagonal shapes) in an
autocatalytic process during prion replication. The two proteins have
identical primary but different secondary structure. PrPSc is rich in-sheet,
is protease-resistant, and accumulates, recruiting more PrPC for further
cycles of conversion.
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within the ER (35). The UPR has three main branches, all acti-
vated by rising levels of misfolded proteins in the ER. Two of
these (the ATF6 and IRE1 branches) result in transcriptional
changes that increase chaperone expression to enhance correct
protein folding. The third, the PERK/eIF2 branch, results in a
signaling cascade that leads to the transient shutdown of pro-
tein synthesis. Binding immunoglobulin protein (BiP) normally
holds PERK in its inactive state, but when bound to unfolded
proteins, it releases PERK, which autodimerizes and autophos-
phorylates. Phosphorylated PERK (PERK-P) phosphorylates
eIF2, which then inhibits the formation of the ternary com-
plex that loads the 40 S ribosome onto the mRNA strand to be
translated (36). Phosphorylated eIF2 (eIF2-P) binds tightly
to eIF2B, the guanine exchange factor that supplies the energy
for the formation of the ternary complex, preventing it from
supplying the GTP needed for loading to take place.
Thus, induction of theUPR leads to complex changes includ-
ing the translation of molecular chaperones, the synthesis of
lipids to increase ER volume, and a reduction in global protein
synthesis to alleviate effects of overload of unfolded proteins
inside the ER. UPR activation is usually a transient event;
eIF2-P is rapidly dephosphorylated by expression of the phos-
phatase GADD34/PP1, allowing normal protein translation to
restart (37).
The UPR in Prion Neurotoxicity
We analyzed activation of the UPR during rising levels of
prion protein accumulation during the course of disease (see
Fig. 3) as PrP is synthesized in the ER. We found that there
was a progressive increase in PERK-P and eIF2-P as the
disease progressed (see Fig. 3a). GADD34 levels did not
change, despite the rising eIF2-P levels, suggesting that
there was insufficient GADD34 to dephosphorylate the
increased amounts of eIF2-P. This shows that the PERK/
eIF2 arm of the UPR is activated in prion disease, inhibiting
protein translation and leading to a reduction in the levels of
synaptic proteins. We also examined mice expressing even
higher levels of PrP, with faster prion incubation times, and
wild type mice. In each case, rising levels of misfolded prion
protein triggered sustained activation of eIF2-P and reduc-
tion in protein synthesis at a stage consistently 75%
through the incubation period.
We measured total protein synthesis rates in the hip-
pocampus via incorporation of radioactive methionine into
protein in hippocampal slices, and also measured translation
of specific mRNA by polysome profiling. A 50% decline in
global protein synthesis was observed (see Fig. 3b), with a
simultaneous reduction in the overall number of actively
translating ribosomes at 9 wpi (33). Northern blots of
SNAP-25 and -actin mRNA also showed reduced active
translation. In contrast ATF4mRNA, which escapes eIF2-P
mediated inhibition of translation due to the presence of
upstream open reading frames in its 5-UTR (38), showed
increased active translation. PrP mRNA did not show
reduced translation, likely due to the presence of similar
translational control elements within the PrP gene as ATF4.
Therapeutic Manipulation of the UPR in Prion
Neurodegeneration
Although transient eIF2 phosphorylation is beneficial to
cells experiencing ER stress due to misfolded proteins, persis-
tently high levels of eIF2-P are likely to be detrimental. To test
whether eIF2-P is directly involved in prion neurodegenera-
tion in vivo, we asked whether reducing the levels of eIF2-P in
prion disease would be neuroprotective. To do this, we overex-
pressed GADD34 using a lentiviral vector, to reduce eIF2-P
levels directly, and in parallel we used targeted RNAi of PrP to
remove the source of UPR activation and prevent eIF2-P for-
mation (Fig. 2). We also asked whether increased levels of
eIF2-P exacerbate prion neurotoxicity by using salubrinal, an
inhibitor of eIF2-P dephosphorylation.
At 9 wpi, mice injected with a lentivirus expressing GADD34
showed a similar level of PERK-P as untreated mice, demon-
strating that the UPR was still being activated, but eIF2-P lev-
els were reduced (Fig. 3) (33). RNAi against PrP prevented the
PrP-induced rise in PERK-P and eIF2-P seen in untreated ani-
mals, confirming prevention of UPR activation. Both GADD34
overexpression and PrP knockdown restored global translation
rates at 9wpi. As a result, synaptic protein levels, synaptic trans-
mission, and synapse number in prion-diseased mice treated
with GADD34 or PrP knockdown were protected and equiva-
lent to levels in uninfected control mice. Burrowing deficits
were prevented, and there was extensive neuronal protection in
the hippocampus, with no neuronal loss andmarkedly reduced
spongiform change (Fig. 3). Importantly, targeted expression of
GADD34 and focal PrP knockdown had a modest, but highly
















FIGURE2.Schematic representationofPERKbranchof theUPR leading to
translational repression and points of intervention. Rising levels of mis-
folded proteins are detected by binding immunoglobulin protein (BiP) in the
ER, activating PERK, which autophosphorylates, and in turn phosphorylates
eIF2, resulting in reduced translation. The decline in protein synthesis leads
to the loss of key proteins, and hence synaptic failure and neurodegenera-
tion. The points of action of GSK2606414, (a specific inhibitor of PERK), of
lentivirus mediating RNAi of PrP (LV-shPrP), and of lentivirus overexpressing
the eIF2-P phosphatase, GADD34/PP1 (LV-GADD34) are shown. By inhibit-
ing/preventing PERK phosphorylation (GSK2606414 and LV-shPrP) or
dephosphorylatingeIF2-P (LV-GADD34), protein synthesis is restored. (Salu-
brinal prevents dephosphorylation of eIF2-P, exacerbating the reduction of
translation.)
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Critically, treatment with salubrinal had the opposite effect,
by preventing dephosphorylation of eIF2-P. Thus, eIF2-P
levels were markedly higher at 9 wpi than in prion-only con-
trols, causing further repression of global translation. Salubri-
nal treatment resulted in earlier severe neuronal loss and sig-
nificantly accelerated disease when compared with untreated
prion-infected mice.
The striking neuroprotection achieved by genetic manipula-
tion of the UPR led us to predict that pharmacological inhibi-
tion of PERK/eIF2-P would be similarly protective.We used a
highly selective inhibitor of PERK GSK2606414 (39), originally
designed as an anticancer compound (Fig. 2). We therefore
treated prion-infected tg37 mice with GSK2606414, adminis-
tered orally, from 7 weeks post infection. The PERK inhibitor
prevented high levels of eIF2-P and restored global protein
synthesis rates. As with genetic manipulation of the UPR, the
mice were clinically cured (32) and there was marked neuro-
protection throughout the brain (Fig. 4), although effects on
survival could not be assessed due to exocrine pancreatic tox-
icity associated with the compound, which resulted in weight
loss necessitating termination of the experiment, despite the
absence of prion clinical signs. The beneficial effects held true
for animals treated both at the preclinical stage and also later in
disease, when behavioral signs had emerged (32). Critically, the
compound acts downstream, and independently, of the pri-
mary pathogenic process of prion replication and is effective
despite continuing accumulation of PrP. Interestingly, we think
the UPR is triggered by rising levels of total PrP synthesis in the
ER rather than as a direct effect of aggregation of PrPSc as this
occurs largely extracellularly, or within the endosomal com-
partment. We previously found that total PrP mRNA levels
increase during prion infection, suggesting that increased syn-
thesis of native PrP may cause misfolding and UPR activation
(33), and there is evidence that overexpression of protein pro-
duction can induce UPR markers (40).
Wider Relevance of UPR Activation in
Neurodegeneration: Restoring Global Protein Synthesis
Is Good for Neurons
Increased levels of UPR activation and PERK-P and eIF2-P
have been described in the brains of Alzheimer disease, Parkin-
son disease, and prion disease patients (41–45), and genetic
polymorphisms in PERK predispose to the tauopathy progres-
sive supranuclear palsy (46). The significance of UPR overacti-
vation is not clear, but several strands of evidence suggest that
here too, promoting protein synthesis where this is chronically
FIGURE3.Manipulationof theUPR rescues translationand isneuroprotective inprion-diseasedmice.a, lentivirallymediatedRNAi against PrP (blue bars)
or overexpression of GADD34 (green) reduces levels of eIF2-P. LV-shPrP, lentivirus mediating RNAi of PrP; LV-GADD34, lentivirus overexpressing the eIF2-P
phosphatase, GADD34/PP1.b, restoring synapsenumber, global protein synthesis rates, burrowingbehavior, andneuronal cell numberswhen comparedwith
untreated prion-diseased mice (black) or empty vector controls (gray). Salubrinal (orange) had a detrimental effect in the same experiments. All data in bar
charts show mean S.E. *, p 0.01; **, p 0.001; ***, p 0.005. c, neuroprotective effects of RNAi of PrP or GADD34 overexpression in CA1 pyramidal cell
ribbon of hippocampus from prion-diseased mice. Adapted from Ref. 33.
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inhibited would be neuroprotective. Learning and memory
depend on protein synthesis (47), and recent evidence has
shown that inhibition of this pathway increases cognition in
wild type mice (48) and prevents cognitive deficits in an
Alzheimer disease mousemodels (49). Restoring protein trans-
lation in aDrosophila and a mammalian neuronal cell model of
amyotrophic lateral sclerosis using GSK2606414 has also
shownbenefits in reducing toxicity (50). The data therefore link
this pathway with memory and cognition as well as with global
neuronal health and viability in health and disease. The data
support drug development programs targeting PERK and other
members of this pathway for the treatment of prion, and poten-
tially other UPR-inducing, neurodegenerative diseases such as
Alzheimer and Parkinson diseases.
Concluding Comments
The relationship between toxicity and infectivity in prion
disease and other protein misfolding disorders is complex, and
we have made our case for targeting the downstream effects of
unfolded protein accumulation. However, intuitively, contain-
FIGURE 4. PERK inhibition by GSK2606414 prevents clinical disease in prion-infectedmice. a, mice were treated with GSK2606414 (blue) or vehicle (red)
from 7 wpi. b–c, GSK2606414 restored global protein synthesis rates (b), prevented loss of novel object memory (c), and affordedmarked neuroprotection in
hippocampus (d). e, levels of total PrP and PrPSc (as shown by proteinase K digestion (PK)) were unaffected by treatment. f and g, clinical cure in treated mice
with normal posture andmovement of hind legs. All data in bar charts showmean S.E. Controls represent mice inoculated with normal brain homogenate
(white bar) (n 12 for each) (*, p 0.01). Adapted from Ref. 32.
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ing spread and reducing the stimulus toUPR inductionmust be
beneficial, preventing the progression that characterizes the
clinical evolution of these diseases as further brain regions
are “recruited” over time. The question is how to do this. One
approach is to administer disease-specific anti-misfolded-pro-
tein antibodies, which has been proposed for Tau and SOD1
(see Holmes and Diamond (54) review in this series). Alterna-
tively, are there generic mechanisms of spread that could be
targeted? It is clear that there are common structural features of
oligomeric forms of these proteins; antibodies raised against
oligomers of PrP also detect oligomeric forms of a number of
other amyloid proteins, including A (51). If such structural
features were involved in a universal protein propagation
mechanism, they could represent a common therapeutic target
for many neurodegenerative diseases. Further, there may be
generic cellular pathways, including exosomal and synaptic
release mechanisms, underlying pathological spreading that
could also potentially be targeted. Indeed, the neuroanatomical
basis for this propagation was recently established by the dem-
onstration of trans-synaptic spread of mutant Tau (39, 52),
although exactly how this occurs is still unclear.
In summary, the discovery of generic phenomena, such as the
spread of misfolded proteins and the effects of these on proteo-
stasis, bring stimulating new insights into neurodegenerative
diseases that may lead to new therapeutic approaches. How-
ever, we still need to understand much more both about these
processes at a molecular level and about how cell-autonomous
and non-cell-autonomous mechanisms relate to each other in
these disorders before we can determine the balance needed
when targeting these processes for therapy.
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